Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans.
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
29 01 2019
29 01 2019
Historique:
received:
04
07
2018
accepted:
13
11
2018
pubmed:
20
11
2018
medline:
13
11
2019
entrez:
20
11
2018
Statut:
ppublish
Résumé
In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.
Identifiants
pubmed: 30452666
pii: 5187947
doi: 10.1093/infdis/jiy565
pmc: PMC6350948
doi:
Substances chimiques
Ebola Vaccines
0
Vaccines, Synthetic
0
Banques de données
ClinicalTrials.gov
['NCT02283099']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
556-561Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P020321/1
Pays : United Kingdom
Investigateurs
Claire-Anne Siegrist
(CA)
Angela Huttner
(A)
Marylyn M Addo
(MM)
Stephan Becker
(S)
Verena Krähling
(V)
Phillip Bejon
(P)
Patricia Njuguna
(P)
Francis Ndungu
(F)
Peter G Kremsner
(PG)
Jessica S Brosnahan
(JS)
Selidji Todagbe Agnandji
(ST)
Sanjeev Krishna
(S)
Marie Paule Kieny
(MP)
Kayvon Modjarrad
(K)
Vasee Moorthy
(V)
Patricia Fast
(P)
Barbara Savarese
(B)
Olivier Lapujade
(O)
Références
J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81
pubmed: 21987744
Science. 2015 Aug 14;349(6249):739-42
pubmed: 26249231
Emerg Infect Dis. 2015 Feb;21(2):305-7
pubmed: 25625358
Virology. 2009 Jan 20;383(2):348-61
pubmed: 19010509
Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469
pubmed: 28647166
Semin Immunol. 2018 Oct;39:65-72
pubmed: 30041831
J Virol. 2002 Apr;76(7):3329-37
pubmed: 11884558
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
EBioMedicine. 2017 May;19:107-118
pubmed: 28434944
Lancet. 2015 Jun 6;385(9984):2272-9
pubmed: 25817373
Nat Med. 2016 Dec;22(12):1439-1447
pubmed: 27798615
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Sci Transl Med. 2015 Apr 1;7(281):281ra43
pubmed: 25834109
Clin Vaccine Immunol. 2017 Nov 6;24(11):
pubmed: 28931520